Melanie Morrison is a leader in Clinical Development and Project Management with 20 years of experience driving corporate transitions from early stage to late stage clinical development organizations. Ms. Morrison is currently Vice President, Clinical Operations, Data & Systems at Nuvation Bio, a biotechnology company focusing on the foremost unmet needs in oncology. Prior to Nuvation, Ms. Morrison was at Aduro Biotech, where she served as interim Project Team Leader for one of its lead oncology assets, Chief of Staff, and Vice-President, Process Optimization. She also served as the Vice President, Oncology Platform Lead at Immune Design (now part of Merck & Co) leading the Clinical Operations and Project Management groups as well as managing the core team for its oncology assets. Ms. Morrison was Vice President, Clinical Operations for Medivation prior to its acquisition by Pfizer. In this role, she oversaw the development and execution of clinical development plans, functional resourcing for a team of approximately 100 employees, and budgeting for 40+ studies. Ms. Morrison was at Genentech from 1999 to 2007 in roles with increasing responsibility within Clinical Operations and Project Management supporting Genentech’s oncology pipeline. She holds a Master of Science in Health Sciences from The George Washington University School of Medicine and Health Sciences and a Bachelor of Science from UC Davis. She holds numerous certifications in regulatory affairs, project management, clinical research management, and public health from such organizations as UC Berkeley, UC Santa Cruz, and UNC Chapel Hill. Ms. Morrison is also an Executive Scholar in Leadership from the Kellogg School of Management